In 2023, cardiac glycosides sales in Italy were valued at 4 million USD. Forecasts indicate a decline from 3.8 million USD in 2024 to 3.1 million USD by 2028. The year-on-year variations illustrate a consistent downward trend: -7.9% from 2024 to 2025, -2.9% from 2025 to 2026, -5.9% from 2026 to 2027, and -3.1% from 2027 to 2028. The five-year compound annual growth rate (CAGR) from 2024 is projected to be negative, reinforcing this declining trend.
Future trends to watch for include:
- Market shifts due to advancements in alternative cardiovascular treatments.
- Potential regulatory changes affecting cardiac glycoside prescriptions.
- Emerging healthcare technologies improving patient care and treatment options.
- Economic factors that might influence healthcare spending and pharmaceutical market dynamics in Italy.
